[go: up one dir, main page]

FI935036A0 - 1H-Imidazol-1-yl-metyl-bensofuranderivat, daer imidazolylgruppen aer substituerade med cykloalkylgrupp - Google Patents

1H-Imidazol-1-yl-metyl-bensofuranderivat, daer imidazolylgruppen aer substituerade med cykloalkylgrupp

Info

Publication number
FI935036A0
FI935036A0 FI935036A FI935036A FI935036A0 FI 935036 A0 FI935036 A0 FI 935036A0 FI 935036 A FI935036 A FI 935036A FI 935036 A FI935036 A FI 935036A FI 935036 A0 FI935036 A0 FI 935036A0
Authority
FI
Finland
Prior art keywords
groups
benzofurans
imidazol
substituted
methyl
Prior art date
Application number
FI935036A
Other languages
English (en)
Other versions
FI935036A7 (fi
Inventor
Barry Clive Ross
David Middlemiss
David Ian Carter Scopes
Torquil Iain Maclean Jack
Kevin Stuart Cardwell
Michael Dennis Dowle
Duncan Bruce Judd
Stephen Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FI935036A0 publication Critical patent/FI935036A0/fi
Publication of FI935036A7 publication Critical patent/FI935036A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI935036A 1991-05-16 1993-11-15 1h-imidazol-1-yl-metyl-bensofuranderivat, daer imidazolylgruppen aer substituerade med cykloalkylgrupp FI935036A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919110636A GB9110636D0 (en) 1991-05-16 1991-05-16 Chemical compounds
PCT/GB1992/000888 WO1992020674A1 (en) 1991-05-16 1992-05-15 1h-imidazol-1-yl-methyl benzofuran derivatives, with the imidazolyl moiety being substituted by a cycloalkyl group

Publications (2)

Publication Number Publication Date
FI935036A0 true FI935036A0 (fi) 1993-11-15
FI935036A7 FI935036A7 (fi) 1993-11-15

Family

ID=10695121

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935036A FI935036A7 (fi) 1991-05-16 1993-11-15 1h-imidazol-1-yl-metyl-bensofuranderivat, daer imidazolylgruppen aer substituerade med cykloalkylgrupp

Country Status (21)

Country Link
US (2) US5332831A (fi)
EP (1) EP0514198B1 (fi)
JP (1) JPH06211846A (fi)
KR (1) KR920021541A (fi)
AP (1) AP318A (fi)
AT (1) ATE169297T1 (fi)
AU (2) AU1692692A (fi)
BG (1) BG98216A (fi)
CA (1) CA2068766A1 (fi)
CZ (1) CZ243093A3 (fi)
DE (1) DE69226472D1 (fi)
FI (1) FI935036A7 (fi)
GB (1) GB9110636D0 (fi)
IL (1) IL101882A0 (fi)
IS (1) IS1609B (fi)
MX (1) MX9202281A (fi)
NO (1) NO921944L (fi)
OA (1) OA09841A (fi)
SK (1) SK112893A3 (fi)
TW (1) TW221998B (fi)
WO (1) WO1992020674A1 (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
US5336779A (en) * 1992-10-08 1994-08-09 Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha Method of producing formylimidazoles
DE69624253T2 (de) * 1995-10-06 2003-08-07 Novartis Ag, Basel Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
US6174910B1 (en) 1996-02-29 2001-01-16 Novartis Ag AT1 receptor antagonist for the stimulation of apoptosis
KR100567183B1 (ko) * 1997-11-14 2006-06-13 론자 아게 포르밀이미다졸의제조방법
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
ID29856A (id) 1998-12-23 2001-10-18 Novartis Ag Penggunaan antagonis reseptor at-1 atau modulator reseptor at-2 untuk mengobati penyakit yang berkaitan dengan peningkatan reseptor-reseptor at-1 atau at-2
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
CA2379666C (en) * 1999-07-21 2009-10-13 Takeda Chemical Industries, Ltd. Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
EP1313470A4 (en) * 2000-08-17 2005-02-16 Gliatech Inc NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
CN101479299B (zh) * 2006-05-05 2012-08-15 陶氏环球技术有限责任公司 杂环有机配体的铪配合物
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
JP5072675B2 (ja) 2007-04-03 2012-11-14 四国化成工業株式会社 ２−ハロイミダゾール化合物の製造方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
CN110256382A (zh) * 2019-06-06 2019-09-20 武汉药明康德新药开发有限公司 一种2-(5-甲基苯并呋喃-2-基)苯甲腈的合成方法
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
US20250195525A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1389827A (en) * 1971-07-23 1975-04-09 Fisons Ltd Tetrazolyl benzopyrans
JPS54148788A (en) * 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
ZA824343B (en) * 1981-07-01 1983-04-27 Upjohn Co Pyridinyl- and imidazolyl-benzofurane and benzothiophenes
JPS6163671A (ja) * 1984-09-05 1986-04-01 Shionogi & Co Ltd ２，３−ジヒドロベンゾフラン−５−スルホンアミド誘導体および降圧利尿剤
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
DE69033469T2 (de) * 1989-06-14 2000-09-07 Smithkline Beecham Corp., Philadelphia Imidazoalkensäure
FI916129A7 (fi) * 1989-06-30 1991-12-27 Du Pont Substituoituja imidatsoleja
FI916130A7 (fi) * 1989-06-30 1991-12-27 Du Pont Aryylisubstituoituja imidatsoleja
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
AU640417B2 (en) * 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5190942A (en) * 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
NO921951L (no) * 1991-05-16 1992-11-17 Glaxo Group Ltd Benzofuran-derivater
DE4140519A1 (de) * 1991-12-09 1993-06-17 Merck Patent Gmbh Benzofurane

Also Published As

Publication number Publication date
ATE169297T1 (de) 1998-08-15
DE69226472D1 (de) 1998-09-10
CA2068766A1 (en) 1992-11-17
MX9202281A (es) 1992-11-01
IL101882A0 (en) 1992-12-30
US5498722A (en) 1996-03-12
AU654350B2 (en) 1994-11-03
NO921944D0 (no) 1992-05-15
CZ243093A3 (en) 1994-03-16
TW221998B (fi) 1994-04-01
US5332831A (en) 1994-07-26
AP318A (en) 1994-02-15
JPH06211846A (ja) 1994-08-02
AU1692692A (en) 1992-12-30
NO921944L (no) 1992-11-17
FI935036A7 (fi) 1993-11-15
IS1609B (is) 1996-10-18
OA09841A (en) 1994-08-15
KR920021541A (ko) 1992-12-18
BG98216A (en) 1994-08-15
SK112893A3 (en) 1994-11-09
AU1632192A (en) 1993-03-11
EP0514198A1 (en) 1992-11-19
EP0514198B1 (en) 1998-08-05
IS3865A (is) 1992-11-17
WO1992020674A1 (en) 1992-11-26
GB9110636D0 (en) 1991-07-03

Similar Documents

Publication Publication Date Title
FI935036A0 (fi) 1H-Imidazol-1-yl-metyl-bensofuranderivat, daer imidazolylgruppen aer substituerade med cykloalkylgrupp
FI931890A7 (fi) Doerr, saerskilt dubbelsidig doerr
FI924831L (fi) Flytande, kontrollerat frigoerande pulversammansaettning
FI934330L (fi) Xylanas, motsvarande rekombinant-dna-sekvens, ett innehaollande xylanassamt anvaendning av medlet
FI935194L (fi) Foerfarande foer dubbelriktad oeverfoering i ett cellulaert mobilradiokommunikationssystem, i vilket foerfarande olika basstationer anvaends foer downlink- och uplink-foerbindelse
FI925721L (fi) Transportabel medicinsk anordning, saerskild infusionsbehandlingsapparat
FI922494L (fi) Pulverformig, enzymer innehaollande diskmedelskomposition foer automatiska diskmaskiner
FI923072L (fi) Maongstegsbindemedel foer anvaendning i elstomerbelaeggningar, mastixbelaeggningar, dikt- och taetningsmedel
FI922493L (fi) Vattenfri, flytande, enzymer innehaollande diskmedelskomposition foer automatiska diskmaskiner
FI925768L (fi) Visuellt klart, gelatigt tandreningsmedel
FI924709L (fi) Pao hartsemulsion baserat ytlimningsmedel, ett daermed limmat papper ochett limningsfoerfarande foer utnyttjande daerav
FI910212A7 (fi) Foerstaerkningsreglering av en agc -foerstaerkare i ett pao tidsmultiplexering baserat radiotelefonsystem.
DE69222122D1 (de) Schwingungsregelsystem
FI922487L (fi) Foerbaettrad vattenfri, flytande, fosfatfri, enzymer innehaollande diskmedelskomposition foer automatiska diskmaskiner
DE69206268D1 (de) Modellunterstüztes regelungssystem.
FI910512A7 (fi) Kontrollsystem.
FI934728L (fi) Stabila, enkomponent, haerdbara epoxi/polyamidhartsdispersioner
DE69201421D1 (de) Systemsteuerungen.
FI921361A0 (fi) Lagerhus foer ett flerradigt rullager.
FI923550A7 (fi) Anordning foer bildning av en fibermatta, saerskilt en mineraluddfibermatta, pao ett stoedband
FI923278A7 (fi) Foerfarande foer sekvensning av signalbehandlingen naer ett digitalt, cellulaert radiosystem aer i foerbindelsetillstaond
DE59201507D1 (de) Federungssystem.
FI922654L (fi) Saekringsanordning foer avtryckarmekanismer, isynnerhet foer eldvapen
FI923279A7 (fi) Foerfarande foer sekvensning av signalbehandlingen naer ett digitalt, cellulaert radiosystem aer i ett begraensat foerbindelsetillstaond
NO912312D0 (no) Styresystem.

Legal Events

Date Code Title Description
FD Application lapsed